scholarly journals An ex vivo tissue model of cartilage degradation suggests that cartilage state can be determined from secreted key protein patterns

2019 ◽  
Author(s):  
Michael Neidlin ◽  
Efthymia Chantzi ◽  
George Macheras ◽  
Mats G Gustafsson ◽  
Leonidas G Alexopoulos

AbstractThe pathophysiology of osteoarthritis (OA) involves dysregulation of anabolic and catabolic processes associated with a broad panel of cytokines and other secreted proteins and ultimately lead to cartilage degradation. An increased understanding about the interactions of these proteins by means of systematic in vitro analyses may give new ideas regarding pharmaceutical candidates for treatment of OA and related cartilage degradation.Therefore, first an ex vivo tissue model of cartilage degradation was established by culturing full thickness tissue explants with bacterial collagenase II. Then responses of healthy and degrading cartilage were analyzed by measuring protein abundance in tissue supernatant with a 26-multiplex protein profiling assay, after exposing them to a panel of 55 protein stimulations present in synovial joints of OA patients. Multivariate data analysis including exhaustive pairwise variable subset selection was used to identify the most outstanding changes in the measured protein secretions. This revealed that the MMP9 response is outstandingly low in degraded compared to healthy cartilage and that there are several protein pairs like IFNG and MMP9 that can be used for successful discrimination between degraded and healthy samples.Taken together, the results show that the characteristic changes in protein responses discovered seem promising for accurate detection/diagnosis of degrading cartilage in general and OA in particular. More generally the employed ex vivo tissue model seems promising for drug discovery and development projects related to cartilage degradation, for example when trying to uncover the unknown interactions between secreted proteins in healthy and degraded tissues.

PLoS ONE ◽  
2019 ◽  
Vol 14 (10) ◽  
pp. e0224231 ◽  
Author(s):  
Michael Neidlin ◽  
Efthymia Chantzi ◽  
George Macheras ◽  
Mats G. Gustafsson ◽  
Leonidas G. Alexopoulos

Lab on a Chip ◽  
2013 ◽  
Vol 13 (18) ◽  
pp. 3555 ◽  
Author(s):  
Beren Ataç ◽  
Ilka Wagner ◽  
Reyk Horland ◽  
Roland Lauster ◽  
Uwe Marx ◽  
...  
Keyword(s):  
Ex Vivo ◽  

2021 ◽  
Vol 20 (4) ◽  
pp. 23s-28s
Author(s):  
Rebecca Barresi ◽  
Emily Chen ◽  
I-Chien Liao ◽  
Xue Liu ◽  
Nada Baalbaki ◽  
...  

2021 ◽  
Author(s):  
Yoshiaki Yasuno ◽  
Ibrahim Abd El-Sadek ◽  
Arata Miyazawa ◽  
Larina Tzu-Wei Shen ◽  
Thitiya Seesan ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Lyess Allas ◽  
Sybille Brochard ◽  
Quitterie Rochoux ◽  
Jules Ribet ◽  
Cleo Dujarrier ◽  
...  

Abstract Histone methyltransferase EZH2 is upregulated during osteoarthritis (OA), which is the most widespread rheumatic disease worldwide, and a leading cause of disability. This study aimed to assess the impact of EZH2 inhibition on cartilage degradation, inflammation and functional disability. In vitro, gain and loss of EZH2 function were performed in human articular OA chondrocytes stimulated with IL-1β. In vivo, the effects of EZH2 inhibition were investigated on medial meniscectomy (MMX) OA mouse model. The tissue alterations were assayed by histology and the functional disabilities of the mice by actimetry and running wheel. In vitro, EZH2 overexpression exacerbated the action of IL-1β in chondrocytes increasing the expression of genes involved in inflammation, pain (NO, PGE2, IL6, NGF) and catabolism (MMPs), whereas EZH2 inhibition by a pharmacological inhibitor, EPZ-6438, reduced IL-1β effects. Ex vivo, EZH2 inhibition decreased IL-1β-induced degradation of cartilage. In vivo, intra-articular injections of the EZH2 inhibitor reduced cartilage degradation and improved motor functions of OA mice. This study demonstrates that the pharmacological inhibition of the histone methyl-transferase EZH2 slows the progression of osteoarthritis and improves motor functions in an experimental OA model, suggesting that EZH2 could be an effective target for the treatment of OA by reducing catabolism, inflammation and pain.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4864-4864
Author(s):  
Bing Xu ◽  
Xiangmeng Wang ◽  
Peng Li ◽  
Yiren Xiao ◽  
Huijuan Dong ◽  
...  

Abstract Erythroid blasts are progenitors that can differentiate to mature red blood cells (RBC). Identification of these growth factors and understanding their downstream pathways can help us to optimize RBC production ex vivo. We derived a stromal cell line (PL16) from mouse embryonic fetal livers that promotes proliferation of mouse and human erythroid blasts in vitro. Among specifically highly expressed secreted proteins in PL16, we identified a new growth factor (FA) that is capable of stimulating human erythroid blast expansion in vitro significantly. Furthermore, erythroid blasts from our in vitro expansion system can differentiate into functional mature red blood cells. Disclosures: No relevant conflicts of interest to declare.


2017 ◽  
Vol 22 (4) ◽  
pp. 048001
Author(s):  
Thomas C. Hutchens ◽  
David A. Gonzalez ◽  
Luke A. Hardy ◽  
C. Scott McLanahan ◽  
Nathaniel M. Fried

2008 ◽  
Vol 103 ◽  
pp. S504
Author(s):  
Michael Smith ◽  
Jennifer Chang ◽  
Susana Gonzalez ◽  
Reuben Garcia-Carrasquillo ◽  
Peter Stevens
Keyword(s):  
Ex Vivo ◽  
Upper Gi ◽  

Sign in / Sign up

Export Citation Format

Share Document